Prostate cancer study questions routine lymph node removal
NCT ID NCT04269512
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether removing lymph nodes during prostate cancer surgery helps prevent the cancer from coming back in men with intermediate-risk prostate cancer. Currently, the procedure is standard but can cause side effects like swelling, blood clots, or nerve injury. The trial will compare PSA recurrence rates and quality of life in 3650 men who either get lymph node removal or not, to see if the extra surgery is worth it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 3,650 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2019
- Expected to finish
-
Dec 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * localized intermediate risk prostate cancer (intermediate risk (PSA\> 10 ng / ml - 20 ng / ml or Gleason score 7 or cT category 2b) * scheduled for open radical prostatectomie or DaVinci prostatectomie Exclusion Criteria: * American Society of Anesthesiology Classification\> 3 * Existing contraindications for performing a lymph node dissection * Neoadjuvant hormone therapy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Localized intermediate-risk prostate cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Martini-Klinik am UKE GmbH
Hamburg, 20246, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A scanner in the operating room could show surgeons exactly where prostate cancer remains
- New PET tracer aims to light up hidden cancer targets
- Can daily adaptive radiotherapy spare healthy tissue in prostate cancer?
- Can a radioactive tracer and MRI reveal prostate Cancer's true extent?
- Five-Fraction radiation plus hormone therapy tested against High-Risk prostate cancer
- Can a 10-Hour eating window fight cancer fatigue?